Fostair 100micrograms/dose / 6micrograms/dose inhaler イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

fostair 100micrograms/dose / 6micrograms/dose inhaler

chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - pressurised inhalation - 6microgram/1dose ; 100microgram/1dose

Fostair 200micrograms/dose / 6micrograms/dose inhaler イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

fostair 200micrograms/dose / 6micrograms/dose inhaler

chiesi ltd - beclometasone dipropionate; formoterol fumarate dihydrate - pressurised inhalation - 200microgram ; 6microgram

Fostair 100 microgram/6 microgram per actuation pressurised inhalation solution アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

fostair 100 microgram/6 microgram per actuation pressurised inhalation solution

chiesi farmaceutici s.p.a. - beclometasone dipropionate; formoterol fumarate dihydrate - pressurised inhalation, solution - 100 /6 µg/µg - formoterol and beclometasone

Inuvair 100 µg/dose - 6 µg/dose press. inhal. sol. multidos. cont. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

inuvair 100 µg/dose - 6 µg/dose press. inhal. sol. multidos. cont.

chiesi sa-nv - formoterol fumarate dihydrate 6 µg/dose; beclometasone dipropionate 100 µg/dose - pressurised inhalation, solution - 100 µg/dose - 6 µg/dose - formoterol fumarate dihydrate 6 µg/dose; beclometasone dipropionate 100 µg/dose - formoterol and beclometasone

Inuvair 200 µg/dose - 6 µg/dose press. inhal. sol. multidos. cont. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

inuvair 200 µg/dose - 6 µg/dose press. inhal. sol. multidos. cont.

chiesi sa-nv - beclometasone dipropionate 200 µg/dose; formoterol fumarate dihydrate 6 µg/dose - pressurised inhalation, solution - 200 µg/dose - 6 µg/dose - beclometasone dipropionate 200 µg/dose; formoterol fumarate dihydrate 6 µg/dose - formoterol and beclometasone

Inuvair Nexthaler 100 µg/dose - 6 µg/dose inhal. pwdr. inhaler ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

inuvair nexthaler 100 µg/dose - 6 µg/dose inhal. pwdr. inhaler

chiesi sa-nv - beclometasone dipropionate 100 µg/dose; formoterol fumarate dihydrate 6 µg/dose - inhalation powder - 100 µg/dose - 6 µg/dose - beclometasone dipropionate 100 µg/dose; formoterol fumarate dihydrate 6 µg/dose - formoterol and beclometasone

Inuvair Nexthaler 200 µg/dose - 6 µg/dose inhal. pwdr. inhaler ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

inuvair nexthaler 200 µg/dose - 6 µg/dose inhal. pwdr. inhaler

chiesi sa-nv - formoterol fumarate dihydrate 6 µg/dose; beclometasone dipropionate 200 µg/dose - inhalation powder - 200 µg/dose - 6 µg/dose - beclometasone dipropionate 200 µg/dose; formoterol fumarate dihydrate 6 µg/dose - formoterol and beclometasone

Inuvair Nexthaler 200 µg/dose - 12 µg/dose inhal. pwdr. inhaler ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

inuvair nexthaler 200 µg/dose - 12 µg/dose inhal. pwdr. inhaler

chiesi sa-nv - formoterol fumarate dihydrate 12 µg/dose; beclometasone dipropionate 200 µg/dose - inhalation powder - 200 µg/dose - 12 µg/dose - beclometasone dipropionate 200 µg/dose; formoterol fumarate dihydrate 12 µg/dose - formoterol and beclometasone

Fostair NEXThaler 100micrograms/dose / 6micrograms/dose dry powder inhaler イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

fostair nexthaler 100micrograms/dose / 6micrograms/dose dry powder inhaler

de pharmaceuticals - beclometasone dipropionate; formoterol fumarate dihydrate - inhalation powder - 100microgram/1dose ; 6microgram/1dose

FOSTER 2006 イスラエル - 英語 - Ministry of Health

foster 2006

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/actuation; beclometasone dipropionate anhydrous 200 mcg/actuation - formoterol and beclometasone - foster 200/6 is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.